Literature DB >> 10986989

Synovial fluid from loose hip arthroplasties inhibits human osteoblasts.

M K Andersson1, L Anissian, A Stark, E Bucht, L Felländer-Tsai, J A Tsai.   

Abstract

Aseptic loosening of prosthetic components in patients who have undergone total hip arthroplasty is a major clinical problem. Earlier studies on this topic have focused mainly on different aspects of bone resorption. The current study investigated the influence of synovial fluid from patients who underwent revision surgery because of aseptic loosening and synovial fluid from patients with osteoarthritis on the proliferation of primary cultures of human osteoblasts. Incubation of cells with 10% synovial fluid from patients who had revision surgery significantly inhibited [3H]thymidine incorporation into deoxyribonucleic acid in human osteoblasts compared with control conditions, whereas 10% synovial fluid from patients with osteoarthritis had a significant stimulatory effect. These findings correlate well with clinical features seen in these diseases, such as increased net bone resorption around the prosthesis in patients with loosening, and increased periarticular bone formation in patients with osteoarthritis.

Entities:  

Mesh:

Year:  2000        PMID: 10986989     DOI: 10.1097/00003086-200009000-00024

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Is monocyte chemotactic protein 1 elevated in aseptic loosening of TKA? A pilot study.

Authors:  Vinod Dasa; Jill M Kramer; Sarah L Gaffen; Keith L Kirkwood; William M Mihalko
Journal:  Clin Orthop Relat Res       Date:  2012-07       Impact factor: 4.176

2.  Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients.

Authors:  Martin K Andersson; Pernilla Lundberg; Acke Ohlin; Mark J Perry; Anita Lie; André Stark; Ulf H Lerner
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.